Ivicentamab  (Synonyms: GEN-3009)

Ivicentamab (GEN-3009) is a bispecific antibody targeting CD37 with dual epitopes. Ivicentamab carries an E430G mutation in the Fc region, which efficiently promotes IgG hexamer formation on the surface of target cells. Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody, enabling it to exert complement-dependent cytotoxicity in Daudi lymphoma cells. Ivicentamab is mainly used in lymphoma-related research^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CD37

Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody that promotes on-target IgG hexamerization and enhances complement-dependent cytotoxicity in Daudi lymphoma cells^[1].
Ivicentamab-derived biparatopic bispecific anti-CD37 antibody (0.0–1.0 μg/mL) enhances complement-dependent cytotoxicity in Daudi lymphoma cells and mediates potent target cell lysis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

951  [NCBI]

P11049

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.88 kDa

2364496-42-2

Liquid

Colorless to light yellow

[Ivicentamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized CD37 Protein, Human (HEK293, Fc, HY-P77886) can bind Ivicentamab. The EC₅₀ for this effect is 7.22 ng/mL.

• [1]. Whitehead CA, et al. Stellabody: A novel hexamer-promoting mutation for improved IgG potency. Immunol Rev. 2024;328(1):438-455.  [Content Brief]